Legal & General Group
CADL icon

Legal & General Group’s Candel Therapeutics CADL Stock Holding History

Legal & General Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5K Sell
3,581
-650
-15% -$3.54K ﹤0.01% 3009
2025
Q4 		$23.9K Hold
4,231
– – ﹤0.01% 2956
2025
Q3 		$21.6K Sell
4,231
-156
-4% -$901 ﹤0.01% 3006
2025
Q2 		$22.2K Buy
4,387
+1,288
+42% +$6.63K ﹤0.01% 2965
2025
Q1 		$17.5K Buy
3,099
+902
+41% +$7.37K ﹤0.01% 2984
2024
Q4 		$19.1K Hold
2,197
– – ﹤0.01% 3041
2024
Q3 		$15.2K Hold
2,197
– – ﹤0.01% 3155
2024
Q2 		$13.6K Buy
+2,197
New +$16.5K ﹤0.01% 3194

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's CADL Position: Q1 2026 in Review

Legal & General Group reduced its Candel Therapeutics (CADL) stake by 15% in Q1 2026, selling an estimated $3.54K and leaving 3,581 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

Legal & General Group first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $23.9K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Legal & General Group held 3,581 shares of Candel Therapeutics worth $17.5K as of Q1 2026.
  • Legal & General Group sold 650 Candel Therapeutics shares in Q1 2026, an estimated $3.54K.
  • Candel Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3009 holding.
  • Legal & General Group first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Legal & General Group's Candel Therapeutics position peaked at $23.9K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.